Evidence map›Paper›PMID 39181221›Full record

ArticleNanomedicine : nanotechnology, biology, and medicine2024

In vitro assessment of nanomedicines' propensity to cause palmar-plantar erythrodysesthesia: A Doxil vs. doxorubicin case study.

Edward Cedrone, Abbas Ishaq, Emma Grabarnik, Elijah Edmondson, Sarah Skoczen, Barry W Neun, Matthew Freer, Siannah Shuttleworth, Lisbet Sviland, Anne Dickinson and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nanomedicine : nanotechnology, biology, and medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Edward CedroneNanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, 8560 Progress Drive, Frederick, MD 21701, USA.
Abbas IshaqAlcyomics Ltd., Biosphere Draymans Way, Newcastle Helix, Newcastle upon Tyne NE4 5BX, United Kingdom.
Emma GrabarnikNanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, 8560 Progress Drive, Frederick, MD 21701, USA.
Elijah EdmondsonMolecular Histopathology Laboratory, Laboratory of Animal Sciences Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, 8560 Progress Drive, Frederick, MD 21701, USA.
Sarah SkoczenNanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, 8560 Progress Drive, Frederick, MD 21701, USA.
Barry W NeunNanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, 8560 Progress Drive, Frederick, MD 21701, USA.
Matthew FreerAlcyomics Ltd., Biosphere Draymans Way, Newcastle Helix, Newcastle upon Tyne NE4 5BX, United Kingdom.
Siannah ShuttleworthAlcyomics Ltd., Biosphere Draymans Way, Newcastle Helix, Newcastle upon Tyne NE4 5BX, United Kingdom.
Lisbet SvilandDepartment of Clinical Medicine, Faculty of Medicine, University of Bergen, Norway.
Anne DickinsonAlcyomics Ltd., Biosphere Draymans Way, Newcastle Helix, Newcastle upon Tyne NE4 5BX, United Kingdom. Electronic address: anne.m.dickinson@alcyomics.com.
Marina A DobrovolskaiaNanotechnology Characterization Laboratory, Cancer Research Technology Program, Frederick National Laboratory for Cancer Research sponsored by the National Cancer Institute, 8560 Progress Drive, Frederick, MD 21701, USA. Electronic address: marina@mail.nih.gov.

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
Intramural NIH HHS Z99 CA999999NCI NIH HHS 75N91019D00024
6 · The paper itself

Abstract

Palmar-plantar erythrodysesthesia (PPE), also known as hand and foot syndrome, is a condition characterized by inflammation-mediated damage to the skin on the palms and soles of the hands and feet. PPE limits the successful therapeutic applications of anticancer drugs. However, identifying this toxicity during preclinical studies is challenging due to the lack of accurate in vitro and in vivo animal-based models. Therefore, there is a need for reliable models that would allow the detection of this toxicity early during the drug development process. Herein, we describe the use of an in vitro skin explant assay to assess traditional DXR, Doxil reference listed drug (RLD) and two generic PEGylated liposomal DXR formulations for their abilities to cause inflammation and skin damage. We demonstrate that the results obtained with the in vitro skin explant assay model for traditional DXR and Doxil correlate with the clinical data.

Indexed as

DoxorubicinHand-Foot SyndromePolyethylene GlycolsAntibiotics, AntineoplasticHumansNanomedicineSkinAntibiotics, AntineoplasticDoxorubicinliposomal doxorubicinPolyethylene GlycolsCytokinesHand and foot syndromeInflammationPalmar-plantar erythrodysesthesiaPBMCSkinSkin explant assaySkin lesion

Identifiers

PMID39181221
PMCPMC11513236

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.